We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Commentary · March 02, 2016

What Is a Reasonable Time Lapse After a Prior Stroke for Alteplase?

Written by
James C. Grotta MD


Additional Info

  1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581-1587.
  2. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947.
  3. Ringleb A, Bousser M-G, Ford G, et al. Guidelines for management of ischemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25(5):457-507.
  4. Karlinski M, Kobayashi A, Czlonkowska A, et al. Safe Implementation of Treatments in Stroke-East Registry (SITS-EATS) Investigators. Stroke. 2015;46(11):3184-3189.
  5. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275-282.
  6. Mishra NK, Ahmed N, Davalos A, et al. SITS and VISTA collaborators. Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology. 2011;77(21):1866-1872.
  7. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768-774.
  8. Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial [published correction appears in Lancet. 2012;380:730]. Lancet. 2012;379(9834):2352-2363.

Further Reading